Marc Goodman initiates coverage of $NGEN, says to buy
Leerink Partners initiates coverage of NGEN and issues a price target of $10/share. This is great news for both shareholders and believers in NVG-291. The company will need more $ to ensure we get through human trials before they can start selling their peptide. The higher the stock goes, the better chances we have for NVG-291 getting out to the public.